During the IHC staining of tumor tissues with CD45 (TIL-specific marker), the percentages of CD45 activity in the 5-FU, zotarolimus, and zotarolimus combined with 5-FU groups were 9.5-fold, 8.6-fold, and 10-fold higher than that in the control group, respectively (Figure A7) [88]. This evidence concerns the gene PTPRC and neoplasm.